C-proSP-B: a possible biomarker for pulmonary diseases?
<b><i>Background:</i></b> Detection of surfactant proteins A and D (SP-A and SP-D) in the serum of patients with pulmonary diseases is thought to reflect an injury of the alveolar epithelial barrier and as such serve as a biomarker for these diseases. However, the data for SP...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
May 15,2018
|
| In: |
Respiration
Year: 2018, Volume: 96, Issue: 2, Pages: 117-126 |
| ISSN: | 1423-0356 |
| DOI: | 10.1159/000488245 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1159/000488245 Verlag, Volltext: https://www.karger.com/Article/FullText/488245 
|
| Author Notes: | Nicolas Kahn, Anne-Kathrin Rossler, Katrin Hornemann, Thomas Muley, Ekkehard Grünig, Werner Schmidt, Felix J.F. Herth, Michael Kreuter |
| Summary: | <b><i>Background:</i></b> Detection of surfactant proteins A and D (SP-A and SP-D) in the serum of patients with pulmonary diseases is thought to reflect an injury of the alveolar epithelial barrier and as such serve as a biomarker for these diseases. However, the data for SP-B are limited. <b><i>Objectives:</i></b> The aim of this feasibility study was to assess whether immature SP-B pre-proteins might have value as a possible biomarker for pulmonary diseases. <b><i>Methods:</i></b> In serum samples from patients with different chronic lung diseases (interstitial lung diseases [ILDs], chronic obstructive pulmonary disease, asthma, lung cancer, pulmonary hypertension, inflammation, patients on ventilator support; total <i>n</i> = 283), C-proSP-B was measured using an electrochemiluminescence immunoassay based on mouse monoclonal anti-C-proSP-B antibodies. Levels were correlated to lung functional and clinical parameters. <b><i>Results:</i></b> The highest C-proSP-B levels were detected in the serum of idiopathic pulmonary fibrosis (IPF) patients. In a multivariate analysis, C-proSP-B levels were able to discriminate IPF patients from patients with all other pulmonary diseases (<i>p</i> < 0.0001). No significant correlations were found between C-proSP-B levels and lung function, smoking history, or disease extent. <b><i>Conclusions:</i></b> SP-B pre-proteins might serve as a biomarker in pulmonary diseases with alveolar or interstitial damage such as ILDs, especially in IPF. Their role in the long-term monitoring of such diseases has to be clarified further. |
|---|---|
| Item Description: | Gesehen am 04.11.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1423-0356 |
| DOI: | 10.1159/000488245 |